[
    {
        "id": "osp-11984",
        "type": "article-journal",
        "title": "A 2-year longitudinal evaluation of the iStent inject® system for open-angle glaucoma in East Asian eyes",
        "author": [
            {
                "family": "Teoh",
                "given": "Ru Jian Jonathan"
            },
            {
                "family": "Yogesvaran",
                "given": "Rupini"
            },
            {
                "family": "Cheng",
                "given": "Felicia Foo Yuen"
            },
            {
                "family": "Muji",
                "given": "Roslinah"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/a-2-year-longitudinal-evaluation-of-the-istent-inject-system-for-open-angle-glaucoma-in-east-asian-eyes",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "18",
        "issue": "1",
        "page": "28-32",
        "DOI": "10.4103/ojo.ojo_223_23",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Background: The aim of the study was to assess the midterm efficacy and safety of the iStent glaucoma device in patients with open-angle glaucoma (OAG).\n\nMaterials and methods: We conducted a retrospective case series of all patients implanted with iStent inject® in OAG. Primary outcomes included intraocular pressure (IOP) and the reduction of antiglaucoma medications. Safety outcomes comprised adverse complications, additional surgeries, and postoperative best-corrected visual acuity (BCVA).\n\nResults: Eight eyes from eight patients were included in this series. The mean age was 56.3 ± 17.5 years. Six eyes had primary OAG and two eyes had secondary OAG. The majority of eyes (75%) had mild-to-moderate glaucoma. Five eyes underwent combined surgery, whereas the remaining three eyes underwent a standalone procedure. The mean baseline IOP was 22.9 ± 8.2 mmHg, and the mean IOP at 2 years after the procedure was 13.6 ± 2.8 mmHg. There was a 44.5% (10.2 ± 2.5 mmHg; P = 0.002) IOP reduction over 2 years. There was also a reduction in medication burden from a baseline mean of 3.4 ± 0.7 to 2.0 ± 1.2 (P = 0.17). There was no documented intraoperative adverse complication, whereas one patient required trabeculectomy post iStent for IOP control.\n\nConclusion: iStent inject implantation safely reduced IOP and medication burden up to 24 months postoperative."
    }
]